Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>
NASDAQ | GEMP (Common Stock)
09/18/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Press Releases More
Gemphire Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update08/13/18
Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD08/10/18
Gemphire Provides Update On Development of Gemcabene08/06/18
Investor Events More
There are currently no events scheduled.